Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Bumetanide Reduces Seizure Frequency in Patients With Temporal Lobe Epilepsy Publisher Pubmed



Eftekhari S1, 2 ; Mehvari Habibabadi J3, 4 ; Najafi Ziarani M3 ; Hashemi Fesharaki SS3 ; Gharakhani M3 ; Mostafavi H5, 6 ; Joghataei MT1 ; Beladimoghadam N3, 7 ; Rahimian E3 ; Hadjighassem MR1, 2
Authors

Source: Epilepsia Published:2013


Abstract

Alterations in the balance of K-Na-2Cl cotransporter (NKCC1) and Na-Cl cotransporter (KCC2) activity may cause depolarizing effect of γ-aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy. NKCC1 facilitates accumulation of chloride inside neurons and favors depolarizing responses to GABA. In the current pilot study we provide the first documented look at efficacy of bumetanide, a specific NKCC1 antagonist, on reduction of seizure frequency in adult patients with temporal lobe epilepsy. According to our results, seizure frequency was reduced considerably in these patients. Furthermore, epileptiform discharges decreased in two of our patients. If the efficacy of bumetanide is proven in large scale studies, it can be used as a supplemental therapy in temporal lobe epilepsy. © 2012 International League Against Epilepsy.